Transcept Pharmaceuticals to Host Conference Call to Discuss Preliminary Analysis of Intermezzo(R) Highway Driving Study

Update: Intermezzo (zolpidem tartrate sublingual tablets) Now FDA Approved - November 23, 2011

Call Scheduled for Tuesday, October 19, 2010 at 8:00 a.m. EDT

POINT RICHMOND, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that it will host a conference call to discuss the recently announced preliminary analysis of the Intermezzo® highway driving study.

Conference Call Information


Date: Tuesday, October 19, 2010


Time: 8:00 a.m. ET


Dial-in (U.S.): 877-638-4558


Dial-in (International): 914-495-8537



A simultaneous web cast of the conference call will be available on the Investors section of the Transcept website at www.transcept.com. A replay of the call will be available on the website shortly after the conclusion of the call until November 23, 2010.

A telephone replay of the conference call will be available shortly after the conclusion of the call until end of business October 23, 2010. The replay telephone numbers are 800-642-1687 (U.S.) and 706-645-9291 (International), replay passcode: 19398284.

About Transcept

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. The most advanced Transcept product candidate is Intermezzo® (zolpidem tartrate sublingual tablet), for which a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in September 2008 seeking approval as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. In October 2009, Transcept received a Complete Response Letter from the FDA on the Intermezzo® NDA and is working to respond to issues raised in the letter. Transcept and Purdue Pharmaceutical Products L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States. For further information, please visit the Transcept website at: www.transcept.com.

Contact:

Transcept Pharmaceuticals, Inc.

Greg Mann

Director, Corporate Communications

(510) 215-3567

gmann@transcept.com



SOURCE Transcept Pharmaceuticals, Inc.

CONTACT: Greg Mann, Director, Corporate Communications of Transcept Pharmaceuticals, Inc., +1-510-215-3567, gmann@transcept.com

Web Site: http://www.transcept.com

Posted: October 2010

View comments

Hide
(web2)